GIS
RPRX icon

Grayhawk Investment Strategies’s Royalty Pharma RPRX Stock Holding History

Grayhawk Investment Strategies’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,844
Closed -$56K – 149
2024
Q1 		$56K Buy
+1,844
New +$54.4K 0.05% 69

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Grayhawk Investment Strategies's RPRX Position: Q2 2024 in Review

Grayhawk Investment Strategies sold out of Royalty Pharma (RPRX) in Q2 2024, closing a stake of 1,844 shares — an estimated $56K sold.

Grayhawk Investment Strategies first reported a position in RPRX in Q1 2024 and held it in 1 quarter. The position peaked at $56K in Q1 2024. 378 funds tracked by Wall St. Rank hold RPRX as of Q2 2024.

  • Grayhawk Investment Strategies reported no remaining Royalty Pharma position as of Q2 2024 after selling out during the quarter.
  • Grayhawk Investment Strategies sold 1,844 Royalty Pharma shares in Q2 2024, an estimated $56K.
  • Grayhawk Investment Strategies first reported a position in Royalty Pharma in Q1 2024 and held it in 1 quarter.
  • Grayhawk Investment Strategies's Royalty Pharma position peaked at $56K in Q1 2024.
  • 378 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2024.

Based on Grayhawk Investment Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.